Chondroitin Sulfate
A cartilage glycosaminoglycan sold for knee osteoarthritis. Pharmaceutical-grade products beat placebo for pain in a 604-person trial and slowed joint-space loss in a two-year trial; the Cochrane review rates the pain evidence low quality, and the NIH trial found no benefit. US rheumatologists strongly recommend against it for knee and hip, and conditionally for hand osteoarthritis. If you try it: 800 mg of a pharmaceutical-grade product daily for 12 weeks, then stop if nothing changed.
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Chondroitin Is
Chondroitin sulfate is one of the glycosaminoglycans that give cartilage its ability to hold water and resist compression. Supplements are extracted from bovine, porcine, chicken or fish cartilage, and the molecules vary in chain length and sulfation pattern from one source to another. That variation matters: absorption depends on molecular structure, and in a pharmacokinetic study of fish-cartilage chondroitin, 4 g reached a peak plasma level of 4.87 µg/mL after 8.7 hours. Pharmaceutical-grade chondroitin, registered as a medicine in parts of Europe, is a defined product; supplement chondroitin often is not.
What the Trials Show
- The Cochrane review, 43 trials. In 4,962 people on chondroitin against 4,148 controls, pain under six months fell 10 percentage points more than on control, but the evidence was low quality with high heterogeneity. The chance of a 20% improvement in function was 53 in 100 against 47 in 100, which is high-quality evidence of a small effect. Joint-space loss was 4.7% smaller. Serious adverse events were rarer than on control.
- CONCEPT, 604 people, six months. Pharmaceutical-grade chondroitin 800 mg a day reduced pain by 42.6 mm on a 100 mm scale, celecoxib by 39.5 mm and placebo by 33.3 mm. Chondroitin beat placebo and matched celecoxib. Note the size of the placebo response.
- STOPP, 622 people, two years. Chondroitin 800 mg a day: minimum joint-space loss −0.07 mm against −0.31 mm on placebo; 28% against 41% had meaningful progression.
- The NIH trial, 1,583 people. Chondroitin 1,200 mg a day was 5.3 points better than placebo on response rate, not significant. Its two-year extension found no structural or pain benefit.
The story across the trials is the same one as for glucosamine: positive results cluster in trials of defined pharmaceutical products, and the publicly funded trial is null. The full read is Glucosamine and Chondroitin for Knee Osteoarthritis: What 20 Years of Trials Show.
The Combination
Glucosamine plus chondroitin is how most people buy it, and the combination has the worst data. A six-month trial in 164 people of chondroitin 1,200 mg with glucosamine sulfate 1,500 mg found pain fell 19% on the combination and 33% on placebo: worse than placebo in the intention-to-treat analysis. A two-year trial in 605 people found the pair slowed joint-space narrowing by 0.10 mm with no pain benefit over placebo. A 606-person trial found the combination matched celecoxib, but it had no placebo arm, so it cannot say whether either beat doing nothing.
What the Guidelines Say
The 2019 American College of Rheumatology and Arthritis Foundation guideline strongly recommends against chondroitin for knee and hip osteoarthritis, and against combination products with glucosamine, and conditionally recommends it for hand osteoarthritis on the strength of a single trial. The European society ESCEO places pharmaceutical-grade chondroitin in the first treatment step for knee osteoarthritis. Exercise and weight loss sit underneath both.
Dose
If you try it: 800 mg a day of a pharmaceutical-grade chondroitin sulfate, with food, for 12 weeks. That is the CONCEPT and STOPP dose. Record your pain and function scores beforehand and stop at 12 weeks if they have not moved. Do not start it at the same time as glucosamine; if you feel better you will not know which one, if either, to keep.
Safety
Chondroitin is among the best-tolerated supplements in the osteoarthritis literature; serious adverse events in the Cochrane review were less common than on control. It is structurally related to heparin, and glucosamine-chondroitin products appear in the case reports of raised INR on warfarin, so anticoagulated patients should not start it without their prescriber.
Where It Fits
Chondroitin is an alternative Layer 1 choice in the Knee Osteoarthritis Supplement Trial, for people who prefer it to glucosamine or already tried glucosamine without effect. It is a cartilage-matrix bet, unlike the anti-inflammatory options curcumin and boswellia or the oral-tolerance theory behind undenatured type II collagen.
Stacking Interactions
How Chondroitin Sulfate interacts with other compounds
A six-month trial of chondroitin 1,200 mg plus glucosamine sulfate 1,500 mg found pain improved less than on placebo. A two-year trial found a small structural effect from the pair and no pain benefit. Test one at a time
Short-term pain trials of turmeric extracts show larger effects than chondroitin, with very high heterogeneity
Protocols using Chondroitin Sulfate
Evidence-graded stacks that include this compound
Safety Profile — Tier A
Well-tolerated — strong human evidence
Contraindications
- ●Anticoagulants — chondroitin is a heparin-like molecule; case reports of raised INR with glucosamine-chondroitin products. Use only with the prescriber's agreement and INR checks
- ●Pregnancy and breastfeeding — not studied
Side Effects
- ●Mild nausea or stomach upset; in the Cochrane review serious adverse events were less frequent than on control (Peto OR 0.40)
- ●Product quality varies: supplement-grade chondroitin content and molecular size are inconsistent, and absorption depends on the molecule's structure